{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:34:48Z","timestamp":1792470888170,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012324","name":"Case Western Reserve University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.eprac.2022.07.003","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T04:07:33Z","timestamp":1657944453000},"page":"1187-1195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Management of Mild-to-Moderate Hypertriglyceridemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Vishnu Priya","family":"Pulipati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5285-5858","authenticated-orcid":false,"given":"Betul","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eprac.2022.07.003_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11883-021-00962-z","article-title":"Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis","volume":"23","author":"Hernandez","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"10.1016\/j.eprac.2022.07.003_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"47","key":"10.1016\/j.eprac.2022.07.003_bib3","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40119-020-00170-x","article-title":"Prevalence of US adults with triglycerides \u2265 150 mg\/dl: NHANES 2007-2014","volume":"9","author":"Fan","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.eprac.2022.07.003_bib5","volume":"198","author":"Carroll","year":"2015"},{"issue":"9","key":"10.1016\/j.eprac.2022.07.003_bib6","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.07.003_bib7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacl.2020.04.009","article-title":"The association between triglycerides and incident cardiovascular disease: what is \u201coptimal\u201c","volume":"14","author":"Aberra","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"issue":"10","key":"10.1016\/j.eprac.2022.07.003_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.eprac.2022.07.003_bib9","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.eprac.2022.07.003_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.eprac.2022.07.003_bib11","first-page":"955","article-title":"Measured versus calculated LDL-cholesterol in subjects with type 2 diabetes","volume":"32","author":"Fawwad","year":"2016","journal-title":"Pak J Med Sci"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eprac.2022.07.003_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fendo.2020.00252","article-title":"Causes and consequences of hypertriglyceridemia","volume":"11","author":"Packard","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Pt B","key":"10.1016\/j.eprac.2022.07.003_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.physbeh.2015.06.024","article-title":"Metabolic effects of non-nutritive sweeteners","volume":"152","author":"Pepino","year":"2015","journal-title":"Physiol Behav"},{"issue":"7521","key":"10.1016\/j.eprac.2022.07.003_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nature13793","article-title":"Artificial sweeteners induce glucose intolerance by altering the gut microbiota","volume":"514","author":"Suez","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.eprac.2022.07.003_bib16","first-page":"279","article-title":"Sweeteners and sweetness enhancers","volume":"20","author":"Belloir","year":"2017","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12937-017-0278-x","article-title":"Health outcomes of non-nutritive sweeteners: analysis of the research landscape","volume":"16","author":"Lohner","year":"2017","journal-title":"Nutr J"},{"key":"10.1016\/j.eprac.2022.07.003_bib18","unstructured":"Aspry KE, Kris-Etherton PM, Kirkpatrick C. Very low carbohydrate and ketogenic diets and cardiometabolic risk. Latest in Cardiology. Expert Analysis. American College of Cardiology; 2020. October 7, 2020. Accessed April 2, 2022. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/10\/07\/13\/54\/very-low-carbohydrate-and-ketogenic-diets-and-cardiometabolic-risk"},{"issue":"suppl 6","key":"10.1016\/j.eprac.2022.07.003_bib19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"10","key":"10.1016\/j.eprac.2022.07.003_bib20","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/TP.0b013e3181aa7d04","article-title":"Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations","volume":"88","author":"Tory","year":"2009","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.eprac.2022.07.003_bib23","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/hq0701.092137","article-title":"Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study","volume":"21","author":"Couillard","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"10.1016\/j.eprac.2022.07.003_bib24","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1161\/hc5001.100624","article-title":"Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S","volume":"104","author":"Ballantyne","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.eprac.2022.07.003_bib25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2022.07.003_bib26","first-page":"S125","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"issue":"11","key":"10.1016\/j.eprac.2022.07.003_bib29","first-page":"681","article-title":"Overview of omega-3 fatty acid therapies","volume":"38","author":"Bradberry","year":"2013","journal-title":"P\u00a0T"},{"issue":"5","key":"10.1016\/j.eprac.2022.07.003_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacc.2020.11.060","article-title":"Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC focus seminar","volume":"77","author":"Weinberg","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.eprac.2022.07.003_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"9567","key":"10.1016\/j.eprac.2022.07.003_bib32","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.eprac.2022.07.003_bib33","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT","volume":"78","author":"Gaba","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2022.07.003_bib34","first-page":"A57","article-title":"Reduction in ischemic stroke with icosapent ethyl-insights from REDUCE-IT","volume":"52","author":"Bhatt","year":"2021","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.eprac.2022.07.003_bib35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.eprac.2022.07.003_bib36","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2022.07.003_bib37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"issue":"47","key":"10.1016\/j.eprac.2022.07.003_bib38","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A\u00a0possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.eprac.2022.07.003_bib39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4158\/EP171764.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001011","article-title":"Importance of maintaining a low omega-6\/omega-3 ratio for reducing platelet aggregation, coagulation and thrombosis","volume":"6","author":"DiNicolantonio","year":"2019","journal-title":"Open Heart"},{"key":"10.1016\/j.eprac.2022.07.003_bib41","series-title":"Vascepa (icosapent ethyl). Package insert","year":"2019"},{"issue":"10","key":"10.1016\/j.eprac.2022.07.003_bib42","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm \u2013 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"6A","key":"10.1016\/j.eprac.2022.07.003_bib43","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.eprac.2022.07.003_bib44","doi-asserted-by":"crossref","first-page":"962.e1","DOI":"10.1016\/j.amjmed.2009.03.030","article-title":"Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review","volume":"122","author":"Abourbih","year":"2009","journal-title":"Am J Med"},{"issue":"19","key":"10.1016\/j.eprac.2022.07.003_bib45","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.eprac.2022.07.003_bib46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"issue":"9600","key":"10.1016\/j.eprac.2022.07.003_bib47","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"9677","key":"10.1016\/j.eprac.2022.07.003_bib48","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2022.07.003_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5414\/CPP42212","article-title":"Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome","volume":"42","author":"Wysocki","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2022.07.003_bib50","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/HYPERTENSIONAHA.112.203661","article-title":"Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults","volume":"60","author":"Walker","year":"2012","journal-title":"Hypertension"},{"issue":"9729","key":"10.1016\/j.eprac.2022.07.003_bib51","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.eprac.2022.07.003_bib52","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.07.003_bib53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"9500","key":"10.1016\/j.eprac.2022.07.003_bib54","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.eprac.2022.07.003_bib55","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2022.07.003_bib56","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.07.003_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"10.1016\/j.eprac.2022.07.003_bib58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2018.03.135","article-title":"Molecular association model of PPARalpha and its new specific and efficient ligand, pemafibrate: structural basis for SPPARM\u03b1","volume":"499","author":"Yamamoto","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"10.1016\/j.eprac.2022.07.003_bib59","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-017-0818-x","article-title":"Pemafibrate: first global approval","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.eprac.2022.07.003_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPARalpha modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.eprac.2022.07.003_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosissup.2018.04.470","article-title":"A\u00a0pooled analysis of pemafibrate phase II\/III clinical trials indicated significant improvement in glycemic and liver function-related parameters","volume":"32","author":"Yokote","year":"2018","journal-title":"Atheroscler Supplements"},{"issue":"8","key":"10.1016\/j.eprac.2022.07.003_bib62","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome Analysis of K-877 (a novel selective PPAR\u03b1 modulator (SPPARM\u03b1))-regulated genes in primary human hepatocytes and the mouse liver","volume":"22","author":"Raza-Iqbal","year":"2015","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"3","key":"10.1016\/j.eprac.2022.07.003_bib63","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.07.003_bib64","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/dom.13686","article-title":"Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study","volume":"21","author":"Araki","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2022.07.003_bib65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.eprac.2022.07.003_bib67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.eprac.2022.07.003_bib68","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3\/4","volume":"78","author":"Rosenson","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.eprac.2022.07.003_bib69","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J\u00a0Lipid Res"},{"issue":"8","key":"10.1016\/j.eprac.2022.07.003_bib70","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.07.003_bib71","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.07.003_bib72","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:13:57Z","timestamp":1761516837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22005626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1530891X22005626"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.07.003","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Mild-to-Moderate Hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}